Evolution of CAR-T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies.
- 1Department of Immunology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.
- 2Research Institute for Cell Design Medical Science, Yamaguchi University, Ube, Yamaguchi, Japan.
Abstract
Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of hematologic malignancies and established a new paradigm for engineered cellular immunotherapy. However, its broader clinical application remains constrained by complex autologous manufacturing, high cost, limited scalability, variable product quality, suboptimal efficacy in solid tumors, and treatment-related toxicities. To address these challenges, recent advances in CAR-T cell therapy can be viewed across four interconnected dimensions: functional engineering, manufacturing innovation, alternative cell sources, and in vivo CAR programming. Functional engineering includes cytokine-armored, checkpoint-resistant, multi-targeting, and modular or switchable CAR platforms designed to enhance efficacy, persistence, and safety. In parallel, manufacturing innovations such as shortened culture protocols, automated closed systems, and preservation of less differentiated T-cell states aim to improve product potency while reducing production time and complexity. Alternative cell sources, including allogeneic donor-derived and induced pluripotent stem cell (iPSC)-derived platforms, may further enable standardized, scalable, and potentially off-the-shelf therapies. Finally, in vivo CAR programming has emerged as a fourth dimension in which endogenous immune cells are directly engineered within patients using viral or non-viral gene delivery systems. This review summarizes these interconnected advances and discusses how they may collectively shape the next generation of CAR-based immune therapies.
Related
- Engineering ex vivo T-cell expansion for CAR-T therapy: bridging biological fidelity and bioprocess scalability through platforms, functional consumables, and integrated closed manufacturing
- Tissue engineering strategies from regional functional units to integrated functional reconstruction for intervertebral disc regeneration
- Advances and perspectives of next-generation antitumor antibody-based modalities: Structural innovation and target-driven strategies.
- Immunomodulatory strategies for ex vivo immune cell expansion in adoptive cell therapy: translational and regulatory considerations for clinical manufacturing
- From ice to innovation: the evolution of heart preservation methods
BibTeX
@article{sakoda2026evolution,
title = {{Evolution of CAR-T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies.}},
author = {Yukimi Sakoda},
journal = {Cancer science},
year = {2026},
month = oct,
doi = {10.1111/cas.70567},
url = {https://europepmc.org/article/MED/42894261},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Evolution of CAR-T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies.
AU - Yukimi Sakoda
PY - 2026
DA - 2026/10/18
JO - Cancer science
DO - 10.1111/cas.70567
UR - https://europepmc.org/article/MED/42894261
AB - Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of hematologic malignancies and established a new paradigm for engineered cellular immunotherapy. However, its broader clinical application remains constrained by complex autologous manufacturing, high cost, limited scalability, variable product quality, suboptimal efficacy in solid tumors, and treatment-related toxicities. To address these challenges, recent advances in CAR-T cell therapy can be viewed across four interconnected dimensions: functional engineering, manufacturing innovation, alternative cell sources, and in vivo CAR programming. Functional engineering includes cytokine-armored, checkpoint-resistant, multi-targeting, and modular or switchable CAR platforms designed to enhance efficacy, persistence, and safety. In parallel, manufacturing innovations such as shortened culture protocols, automated closed systems, and preservation of less differentiated T-cell states aim to improve product potency while reducing production time and complexity. Alternative cell sources, including allogeneic donor-derived and induced pluripotent stem cell (iPSC)-derived platforms, may further enable standardized, scalable, and potentially off-the-shelf therapies. Finally, in vivo CAR programming has emerged as a fourth dimension in which endogenous immune cells are directly engineered within patients using viral or non-viral gene delivery systems. This review summarizes these interconnected advances and discusses how they may collectively shape the next generation of CAR-based immune therapies.
SN - 1347-9032
SN - 1349-7006
ER -